Name | Title | Contact Details |
---|
Yield10 Bioscience is an agricultural bioscience company focusing on the development of disruptive technologies to produce step-change improvements in crop yield for food and feed crops to enhance global food security. Experts forecast that food production must be increased by over 70% in the next 35 years to feed the growing global population, which is expected to increase from 7 billion to more than 9.6 billion by 2050. Yield10 is focused on new agricultural biotechnology approaches to improve fundamental elements of plant metabolism through enhanced photosynthetic efficiency and directed carbon utilization. Yield10 is working to develop, validate and commercialize new traits and identify gene editing targets in several key crops including canola, soybean and corn. Yield10 was launched by Metabolix, Inc. in 2015 and is traded on Nasdaq (YTEN). Yield10 is headquartered in Woburn, MA and has an additional agricultural science facility with greenhouses in Saskatoon, Saskatchewan, Canada.
Arcadia Biosciences (Nasdaq: RKDA) develops and markets high-value food ingredients and nutritional oils that help meet consumer demand for a healthier diet. Arcadia`s GoodWheatâ„¢ branded ingredients deliver health benefits to consumers and enable consumer packaged goods companies to differentiate their brands in the marketplace. The company`s portfolio of agricultural traits are being developed to enable farmers around the world to be more productive and minimize the impact of agriculture on the environment.
Talaris Therapeutics is a late-clinical stage biotechnology company based in Boston, MA and Louisville, KY. Talaris is developing transformative cell therapies with the potential to eliminate the burden of chronic immunosuppression for organ transplant recipients as well as induce durable remissions in patients with severe auto-immune and immune-mediated disorders. The company was founded on technology discovered and developed by Dr. Suzanne Ildstad and operates its own cell processing facility in Louisville. Talaris is backed by leading life sciences investors Blackstone Life Sciences, Longitude Capital and Qiming Venture Partners USA.
Octapharma Plasma is a Charlotte, NC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
IDEAYA Biosciences is an oncology-focused biotechnology company committed to the discovery of personalized synthetic lethality medicines targeting DNA damage and repair for genetically defined patient populations and immuno-oncology therapies targeting the tumor microenvironment. Founded in 2015, IDEAYA`s investors include 5AM Ventures (5AM), Canaan Partners (Canaan), Celgene, WuXi Healthcare Ventures (WuXi), Novartis Institute of Biomedical Research, and Alexandria Real Estate. The Company has assembled a world-class drug discovery team and Scientific Advisory Board (SAB) that is represented by a Nobel Laureate and three Members of the National Academy of Sciences. IDEAYA is located in South San Francisco and La Jolla, California.